Riluzole: A new agent for amyotrophic lateral sclerosis

Annals of Pharmacotherapy

Volumn 31, Issue 6, 1997, Pages 738-744

  Wagner, Mary L ^a   Landis, Barbara E ^b  

^a RUTGERS UNIVERSITY   (United States)

^b Rutgers University   (United States)

Author keywords

Amyotrophic lateral sclerosis; Riluzole

Indexed keywords

RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ASTHENIA; DATA ANALYSIS; DATA BASE; DOSE LIVER FUNCTION RELATION; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG INFORMATION; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MEDICAL INFORMATION; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; REVIEW; VERTIGO;

EID: 0030981003     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100614     Document Type: Review

References (51)

1. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991;66:54-82.
2. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escortal: World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):96-107.
3. Kaplan L, Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med 1994;15:675-81.
4. Rowland LP. Riluzole for treatment of amyotrophic lateral sclerosis -too soon to tell? N Engl J Med 1994;330:636-7.
5. Mackay R. Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 1963;8:117-27.
6. Plaitakis A. Altered glutamatergic mechanisms and selective motor neuron degeneration in amyotrophic lateral sclerosis: possible role of glycine. Adv Neurol 1991;56:319-26.
7. Hughes JT. Pathology of amyotrophic lateral sclerosis. In: Rowland LP, ed. Human motor neuron diseases. Vol. 36 of advances in neurology. New York: Raven Press, 1982:61-74.
8. Hugon J, Tabaraud F, Rigaud M, Vallat JM, Dumas M. Glutamate dehydiogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease. Neurology 1989;39:956-8.
9. Swash M, Leigh N. Criteria for diagnosis of familial amyotrophic lateral sclerosis. Neuromuscular Dis 1992;2:7-9.
10. Boss B, Sunderland P, Heath J. Alterations of neurologic function. In: McCance K, Huether S. Pathophysiology: the biologic basis for disease in adults and children. 2nd ed. St. Louis: Mosby-Year Book, Inc., 1994: 576.
11. Appel S, Smith RG. Can neurotrophic factors prevent or reverse motor neuron injury in amyotrophic lateral sclerosis? Exp Neurol 1993;124: 100-2.
12. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: part 1. Clinical features, pathophysiology, and ethical issues in the management. Ann Neurol 1985;8:271-80.
13. Plaitakis A, Mandeli J, Smith J, Yahr M. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet 1988;1:1015-8.
14. Li TM, Alberman E, Swash M. Clinical features and associations of 560 cases of motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53: 1043-5.
15. Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-64.
16. Rothstein J, Martin L, Kuncl R. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8.
17. Mulder MD, Howard FM. Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc 1976;51:537-41.
18. Rosen AD. Amyotrophic lateral sclerosis: clinical features and prognosis. Arch Neurol 1978;35:638-42.
19. Siddique T, Figelwicz DA, Pericak-Vance MA, Haines JL, Roulean G, Jeffers AJ, et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991;324:1381-4.
20. Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;35:142-9.
21. Appel SH, Smith RG, Englehardt JI, Stefani E. Evidence for autoimmunity in ALS. J Neurol Sci 1993;118:1169-74.
22. Adams CR, Ziegler DK, Lin ST. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA 1983;250:642-3.
23. McNamara JO, Fridovich I. Did radicals strike Lou Gehrig? Nature 1993;362:20-1.
24. Lipton S, Rosenberg P. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-20.
25. Frandsen AA, Scousboe A. Excitatory amino acid mediated cytotoxicity and calcium homeostasis in cultured neurons. J Neurochem 1993;60: 1202-11.
26. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic and sulfur containing amino acids of the infant mouse central nervous system. Exp Brain Res 1971;14:61-76.
27. Choi D. Amyotrophic lateral sclerosis and glutamate - too much of a good thing? N Engl J Med 1992;326:1493-4.
28. Data on file, Collegeville, PA: Rhône-Poulenc Rorer.
29. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflügers Arch 1991;419:603-9.
30. Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, et al. 2-Amino-6-triflouromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission - I. Anticonvulsant properties. Neuropharmacology 1985;24:767-73.
31. Package insert. Rilutek (riluzole). Collegeville, PA: Rhône-Poulenc Rorer, Revised December 1995.
32. Miller RG, Bouchard JP, Duquette P, Eilsen A, Gelinas D, Harati Y, et al. Clinical trials of riluzole in patients with ALS. Neurology 1996;47(4 suppl 2):S86-92.
33. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:19-30.
34. Bensimon G, Lacomblez L, Meininger V, the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;30:585-91.
35. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Doseranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347:1425-31.
36. McKee P, Fuller G, Stevens D. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:272.
37. Rowland LP. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:274.
38. MacRae K. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:272-3.
39. Burgerman R. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273.
40. Bensimon G, Lacomblez L, Meininger V. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273-4.
41. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316-22.
42. Murphy JR. Riluzole in amyotrophic lateral sclerosis (letter). N Engl J Med 1994;331:273.
43. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(suppl 6, pt 2): 84S-99S.
44. Shen WW. Cytochrome P450 monooxygenases and interactions of psy-chotropic drugs: a five-year update. Int J Psychiatr Med 1995;25:277-90.
45. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5:259-74.
46. Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995;28:449-57.
47. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-82.
48. Finkel AS, Hammond JM, Karlin DS, Morris S, Petropoulos M, Rosenberg J, et al., eds. 1996 Drug topics red book. Montvale, NJ: Medical Economics Company, Inc., 1996:437.
49. Mitsumoto H, Olney RK. Drug combination treatment in patients with ALS: current status and future directions. Neurology 1996;47(suppl 2): 103-7.
50. Kasarskis EJ, Neville HE. Management of ALS: nutritional care. Neurology 1996;47(suppl 2):118-20.
51. Hopkins LC, Tatarian GT, Pianta TF. Management of ALS: respiratory care. Neurology 1996;47(suppl 2):123-5.